Cortechs.ai licenses technology patents from the University of California San Diego (UCSD)

Technology derived from UCSD researchers to further develop new volumetric imaging products     

(SAN DIEGO) September 11, 2019 – Cortechs.ai, the leader in AI-based brain image quantification, has announced that it has entered into licensing agreements with the University of California San Diego (UCSD), allowing the company to utilize several technologies focused on expanding the role of volumetric magnetic resonance imaging (MRI) in clinical practice.

“These technologies out-licensed from UCSD significantly expand our IP portfolio and will contribute to further development of our flagship product, NeuroQuant® as well as more broadly grow our quantitative MRI focused product lines,” said Dr. Chris Airriess, CEO of Cortechs.ai. “We are excited about the improvements these new technologies will bring to radiology workflow and, most importantly, to patient care in general.”

The technologies licensed from UCSD will allow Cortechs.ai to utilize the specific systems, methods, and software needed to better quantify communications pathways within the brain as well as accurately pinpoint regions of pathology as part of an automated processing stream. Technologies ready for implementation and sub-licensing include advanced techniques for image distortion correction due to magnetic field inhomogeneities, as well as active correction for patient movement in the scanner, which is critical for imaging of some patient populations.

These in-licensed technologies will help Cortechs.ai drive the ongoing evolution of current flagship products, NeuroQuant, LesionQuant™ and PETQuant™, as well as partner with other companies to bring novel AI-based solutions to the volumetric imaging space.

About Cortechs.aiCortechs.ai develops and markets breakthrough medical device software solutions capable of automatically segmenting and quantifying brain structures, making quantitative analysis of the human brain a routine part of clinical practice. Cortechs.ai’ cutting-edge brain imaging analysis provides neurologists, radiologists and clinical researchers worldwide with a convenient and cost-effective means to quantify brain structures to help assess a variety of neurological conditions, such as Alzheimer’s disease, epilepsy, multiple sclerosis, brain trauma and brain development abnormalities. Please visit cortechs.ai for further information and follow us on Twitter, LinkedIn and Facebook.

###

 

More Resources

03/09/2025

Advancing TBI Evaluation with AI-Driven MRI Analysis: A New Era in Brain Health

AI-driven MRI with NeuroQuant® enhances TBI assessment, tracks recovery, and supports better treatment decisions.

03/06/2025

Case Study: Leveraging NeuroQuant® for Accurate Diagnosis of Traumatic Brain Injury

This case highlights the power of advanced neuroimaging tools in delivering precise, evidence-based diagnostics to enhance patient care and clinical decisions.

02/26/2025

Traumatic Brain Injury in Athletes: The Role of the NeuroQuant and Automated Volumetric Tracking

NeuroQuant enables objective brain volume tracking for early TBI detection, recovery monitoring, and safer return-to-play decisions.

02/25/2025

OnQ™ Prostate Solution Enhances Collaboration and Improves MRI for Cancer Detection with RSI Technology

OnQ Prostate enhances MRI tissue characterization, improving sensitivity and specificity in cancer detection, & bridges gaps between radiologists and urologists

02/15/2025

NeuroQuant® Dementia: Advancing Alzheimer’s Disease Care in the Era of DMTs

AI-driven brain volumetric analysis is revolutionizing Alzheimer’s care, providing precise diagnostic support, monitoring, and early detection.

02/09/2025

NeuroQuant® MS:  Advancing Precision in Multiple Sclerosis

Dr. Suzie Bash discusses NeuroQuant MS, noting its ability to segment plaques, analyze volume, and track lesion burden for assessing disease progression
Scroll to Top